| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6159458 | THEA PHARMA | Sustained release ophthalmic compositions containing water soluble medicaments |
Nov, 2017
(6 years ago) | |
| US6861411 | THEA PHARMA | Method of treating eye infections with azithromycin |
Nov, 2018
(5 years ago) | |
| US7056893 | THEA PHARMA | Topical treatment for prevention of ocular infections |
Mar, 2019
(5 years ago) | |
| US6239113 | THEA PHARMA | Topical treatment or prevention of ocular infections |
Mar, 2019
(5 years ago) | |
| US6569443 | THEA PHARMA | Topical treatment or prevention of ocular infections |
Mar, 2019
(5 years ago) | |
Azasite is owned by Thea Pharma.
Azasite contains Azithromycin.
Azasite has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Azasite are:
- US6159458
- US6861411
- US7056893
- US6239113
- US6569443
Azasite was authorised for market use on 27 April, 2007.
Azasite is available in solution/drops;ophthalmic dosage forms.
Azasite can be used as method of combating bacteria in a patient.
The generics of Azasite are possible to be released after 31 March, 2019.
Drugs and Companies using AZITHROMYCIN ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Method of combating bacteria in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of AZASITE before it's drug patent expiration?
More Information on Dosage
AZASITE family patents
